Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations

K. Paik, Paul; Felip, Enriqueta; Veillon, Rémi; Sakai, Hiroshi; B. Cortot, Alexis; Chiara Garassino, Marina; Mazières, Julien; Viteri, Santiago; Senellart, Hélène; P. van Meerbeeck, Jan; Raskin, Jo; Reinmuth, Niels; Conte, PierFranco; M. Kowalski, Dariusz; Chul Cho, Byoung; D. Patel, Jyoti; Horn, Leora; Griesinger, Frank; Han, Ji‐Youn; Kim, Young‐Chul; Chang, Gee‐Chen; Tsai, Chen‐Liang; Chih‐Hsin Yang, James; Chen, Yuh-Min; F. Smit, Egbert; J. van der Wekken, Anthonie; Kato, Terufumi; Juraeva, Dilafruz; Stroh, Christopher; Bruns, Rolf; Straub, Josef; Johne, Andreas; Scheele, J.; V. Heymach, John; Le, Xiuning

doi:10.1056/nejmoa2004407

Public

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Published in New England Journal of Medicine • May 28, 2020

Authors:

Paul K. Paik

Enriqueta Felip

Rémi Veillon

Abstract

BACKGROUND: occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. METHODS: exon 14 skipping mutation was detected on liquid biopsy or tissue biopsy. RESULTS: As of Januar...

Subject

Medicine

Exon

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!